NLS Net Debt vs Net Receivables Analysis

NLSP Stock

USD 3.66 0.10 2.81%

NLS Pharmaceutics financial indicator trend analysis is infinitely more than just investigating NLS Pharmaceutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NLS Pharmaceutics is a good investment. Please check the relationship between NLS Pharmaceutics Net Debt and its Net Receivables accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Net Debt vs Net Receivables

Net Debt vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NLS Pharmaceutics Net Debt account and Net Receivables. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between NLS Pharmaceutics' Net Debt and Net Receivables is 0.52. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Net Receivables in the same time period over historical financial statements of NLS Pharmaceutics AG, assuming nothing else is changed. The correlation between historical values of NLS Pharmaceutics' Net Debt and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of NLS Pharmaceutics AG are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Net Debt i.e., NLS Pharmaceutics' Net Debt and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.52

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Net Receivables

Most indicators from NLS Pharmaceutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NLS Pharmaceutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

At this time, NLS Pharmaceutics' Selling General Administrative is relatively stable compared to the past year. As of 11/27/2024, Enterprise Value is likely to grow to about 1.1 B, while Issuance Of Capital Stock is likely to drop 0.00.

NLS Pharmaceutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital
Total Assets		-0.33	0.08	-0.04	0.89	0.38	0.66	-0.78	-0.46	0.07	0.96	-0.25	-0.25	-0.34	-0.33	0.96	-0.18	0.19	0.22	-0.34	0.13	0.62	-0.63	0.42	0.99	0.61
Short Long Term Debt Total	-0.33		-0.82	-0.81	-0.4	-0.97	-0.73	0.84	0.82	-0.87	-0.13	-0.4	-0.37	-0.28	1.0	-0.13	0.69	-0.9	-0.5	0.99	-0.54	-0.82	0.67	0.66	-0.26	0.45
Other Current Liab	0.08	-0.82		0.99	0.03	0.85	0.55	-0.56	-0.8	0.99	-0.11	0.52	0.51	0.0	-0.83	-0.11	-0.66	0.92	0.56	-0.83	0.61	0.76	-0.15	-0.79	0.02	-0.68
Total Current Liabilities	-0.04	-0.81	0.99		-0.05	0.83	0.47	-0.49	-0.73	0.99	-0.23	0.59	0.58	0.09	-0.83	-0.23	-0.65	0.9	0.5	-0.82	0.57	0.68	-0.13	-0.86	-0.11	-0.76
Total Stockholder Equity	0.89	-0.4	0.03	-0.05		0.45	0.55	-0.82	-0.31	0.06	0.92	-0.15	-0.17	-0.02	-0.39	0.92	-0.14	0.17	-0.03	-0.42	-0.1	0.57	-0.73	0.42	0.89	0.63
Other Liab	0.38	-0.97	0.85	0.83	0.45		0.73	-0.86	-0.8	0.89	0.22	0.42	0.4	0.21	-0.97	0.22	-0.6	0.9	0.44	-0.97	0.49	0.86	-0.57	-0.59	0.31	-0.37
Net Tangible Assets	0.66	-0.73	0.55	0.47	0.55	0.73		-0.82	-0.92	0.56	0.49	-0.24	-0.25	-0.14	-0.72	0.49	-0.68	0.78	0.79	-0.72	0.78	0.91	-0.67	-0.26	0.66	-0.03
Net Debt	-0.78	0.84	-0.56	-0.49	-0.82	-0.86	-0.82		0.74	-0.58	-0.65	-0.14	-0.11	-0.05	0.84	-0.65	0.52	-0.67	-0.36	0.84	-0.35	-0.87	0.81	0.15	-0.73	-0.1
Retained Earnings	-0.46	0.82	-0.8	-0.73	-0.31	-0.8	-0.92	0.74		-0.79	-0.24	0.0	0.01	0.13	0.82	-0.24	0.81	-0.92	-0.86	0.81	-0.86	-0.93	0.5	0.54	-0.44	0.35
Accounts Payable	0.07	-0.87	0.99	0.99	0.06	0.89	0.56	-0.58	-0.79		-0.12	0.55	0.53	0.1	-0.88	-0.12	-0.66	0.94	0.53	-0.87	0.59	0.75	-0.22	-0.82	0.0	-0.69
Cash	0.96	-0.13	-0.11	-0.23	0.92	0.22	0.49	-0.65	-0.24	-0.12		-0.32	-0.32	-0.31	-0.14	1.0	0.01	-0.01	0.01	-0.15	-0.09	0.47	-0.52	0.62	0.97	0.78
Non Current Assets Total	-0.25	-0.4	0.52	0.59	-0.15	0.42	-0.24	-0.14	0.0	0.55	-0.32		1.0	0.18	-0.43	-0.32	-0.02	0.25	-0.32	-0.42	-0.21	0.0	0.07	-0.54	-0.35	-0.56
Non Currrent Assets Other	-0.25	-0.37	0.51	0.58	-0.17	0.4	-0.25	-0.11	0.01	0.53	-0.32	1.0		0.14	-0.4	-0.32	0.01	0.23	-0.32	-0.39	-0.21	-0.01	0.1	-0.53	-0.35	-0.55
Other Assets	-0.34	-0.28	0.0	0.09	-0.02	0.21	-0.14	-0.05	0.13	0.1	-0.31	0.18	0.14		-0.24	-0.31	0.1	0.09	-0.19	-0.24	-0.19	-0.1	-0.27	-0.29	-0.34	-0.23
Long Term Debt	-0.33	1.0	-0.83	-0.83	-0.39	-0.97	-0.72	0.84	0.82	-0.88	-0.14	-0.43	-0.4	-0.24		-0.14	0.71	-0.9	-0.49	1.0	-0.53	-0.82	0.66	0.66	-0.26	0.46
Cash And Short Term Investments	0.96	-0.13	-0.11	-0.23	0.92	0.22	0.49	-0.65	-0.24	-0.12	1.0	-0.32	-0.32	-0.31	-0.14		0.01	-0.01	0.01	-0.15	-0.09	0.47	-0.52	0.62	0.97	0.78
Net Receivables	-0.18	0.69	-0.66	-0.65	-0.14	-0.6	-0.68	0.52	0.81	-0.66	0.01	-0.02	0.01	0.1	0.71	0.01		-0.78	-0.69	0.73	-0.71	-0.72	0.45	0.57	-0.16	0.45
Common Stock Total Equity	0.19	-0.9	0.92	0.9	0.17	0.9	0.78	-0.67	-0.92	0.94	-0.01	0.25	0.23	0.09	-0.9	-0.01	-0.78		0.73	-0.89	0.78	0.87	-0.39	-0.75	0.15	-0.58
Common Stock Shares Outstanding	0.22	-0.5	0.56	0.5	-0.03	0.44	0.79	-0.36	-0.86	0.53	0.01	-0.32	-0.32	-0.19	-0.49	0.01	-0.69	0.73		-0.46	0.98	0.68	-0.25	-0.49	0.23	-0.38
Non Current Liabilities Total	-0.34	0.99	-0.83	-0.82	-0.42	-0.97	-0.72	0.84	0.81	-0.87	-0.15	-0.42	-0.39	-0.24	1.0	-0.15	0.73	-0.89	-0.46		-0.51	-0.83	0.66	0.64	-0.27	0.44
Other Current Assets	0.13	-0.54	0.61	0.57	-0.1	0.49	0.78	-0.35	-0.86	0.59	-0.09	-0.21	-0.21	-0.19	-0.53	-0.09	-0.71	0.78	0.98	-0.51		0.66	-0.23	-0.59	0.14	-0.48
Other Stockholder Equity	0.62	-0.82	0.76	0.68	0.57	0.86	0.91	-0.87	-0.93	0.75	0.47	0.0	-0.01	-0.1	-0.82	0.47	-0.72	0.87	0.68	-0.83	0.66		-0.55	-0.34	0.59	-0.13
Total Liab	-0.63	0.67	-0.15	-0.13	-0.73	-0.57	-0.67	0.81	0.5	-0.22	-0.52	0.07	0.1	-0.27	0.66	-0.52	0.45	-0.39	-0.25	0.66	-0.23	-0.55		0.05	-0.61	-0.18
Net Invested Capital	0.42	0.66	-0.79	-0.86	0.42	-0.59	-0.26	0.15	0.54	-0.82	0.62	-0.54	-0.53	-0.29	0.66	0.62	0.57	-0.75	-0.49	0.64	-0.59	-0.34	0.05		0.48	0.96
Total Current Assets	0.99	-0.26	0.02	-0.11	0.89	0.31	0.66	-0.73	-0.44	0.0	0.97	-0.35	-0.35	-0.34	-0.26	0.97	-0.16	0.15	0.23	-0.27	0.14	0.59	-0.61	0.48		0.66
Net Working Capital	0.61	0.45	-0.68	-0.76	0.63	-0.37	-0.03	-0.1	0.35	-0.69	0.78	-0.56	-0.55	-0.23	0.46	0.78	0.45	-0.58	-0.38	0.44	-0.48	-0.13	-0.18	0.96	0.66

Click cells to compare fundamentals

NLS Pharmaceutics Account Relationship Matchups

NLS Pharmaceutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	696.4K	1.2M	5.8M	9.3M	1.8M	3.3M
Short Long Term Debt Total	7.1M	842.1K	2.1M	1.6M	1.5M	1.4M
Other Current Liab	835.7K	1.4M	666.4K	986.4K	1.7M	1.0M
Total Current Liabilities	4.0M	7.2M	2.4M	3.4M	7.9M	4.5M
Total Stockholder Equity	(6.2M)	(9.0M)	542.4K	3.3M	(8.8M)	(9.3M)
Other Liab	159.0K	2.7M	2.7M	2.8M	3.2M	1.9M
Net Tangible Assets	(8.8M)	(6.2M)	(9.0M)	542.4K	623.7K	654.9K
Net Debt	621.9K	2.0M	(5.4M)	(8.9M)	736.1K	772.9K
Retained Earnings	(26.9M)	(29.8M)	(41.7M)	(58.2M)	(70.4M)	(66.9M)
Accounts Payable	2.5M	4.0M	1.7M	2.4M	4.6M	2.7M
Cash	220.3K	93.7K	5.4M	8.9M	897.7K	852.8K
Non Current Assets Total	314.7K	1.0M	41.6K	30.2K	23.6K	22.4K
Non Currrent Assets Other	260.2K	946.9K	12.0K	12.1K	16.9K	16.0K
Cash And Short Term Investments	220.3K	93.7K	5.4M	8.9M	897.7K	852.8K
Net Receivables	75.4K	61.2K	38.6K	41.2K	10.7K	10.1K
Common Stock Shares Outstanding	11.1M	4.8M	14.7M	19.7M	38.2M	40.1M
Liabilities And Stockholders Equity	696.4K	1.2M	5.8M	9.3M	1.8M	3.3M
Non Current Liabilities Total	2.8M	3.0M	2.8M	2.6M	2.8M	3.4M
Other Current Assets	86.1K	14.4K	292.0K	191.0K	925.4K	971.7K
Other Stockholder Equity	20.6M	20.6M	42.1M	60.9M	61.0M	35.5M
Total Liab	6.9M	10.2M	5.2M	6.0M	10.7M	6.6M
Net Invested Capital	(5.3M)	(6.9M)	542.4K	3.3M	(7.2M)	(6.8M)
Total Current Assets	381.7K	196.7K	5.7M	9.2M	1.8M	3.1M
Accumulated Other Comprehensive Income	(18.7K)	(19.4K)	(151.7K)	(50.8K)	(158.1K)	(150.2K)
Net Working Capital	(3.7M)	(7.0M)	3.3M	5.9M	(6.1M)	(5.8M)
Inventory	(33.6K)	(61.2K)	(38.6K)	(41.2K)	(37.1K)	(39.0K)
Short Term Debt	690.1K	1.8M	2.5B	1.6M	1.9M	1.8M

Pair Trading with NLS Pharmaceutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NLS Pharmaceutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with NLS Stock

0.8	ME	23Andme Holding	Pair Corr
0.85	VALN	Valneva SE ADR	Pair Corr
0.76	JNJ	Johnson Johnson Sell-off Trend	Pair Corr

Moving against NLS Stock

0.52	MDGL	Madrigal Pharmaceuticals	Pair Corr
0.5	KZR	Kezar Life Sciences	Pair Corr
0.42	NXGLW	NexGel Warrant	Pair Corr
0.4	RNXT	RenovoRx	Pair Corr
0.36	MLYS	Mineralys Therapeutics,	Pair Corr

The ability to find closely correlated positions to NLS Pharmaceutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NLS Pharmaceutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NLS Pharmaceutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NLS Pharmaceutics AG to buy it.

The correlation of NLS Pharmaceutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NLS Pharmaceutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NLS Pharmaceutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for NLS Pharmaceutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC